TSO3 Inc. (TSE:TOS) – Analysts at Desjardins increased their FY2019 earnings per share estimates for shares of TSO3 in a report released on Monday, May 28th, according to Zacks Investment Research. Desjardins analyst F. Tremblay now anticipates that the company will earn ($0.07) per share for the year, up from their previous estimate of ($0.08).
TSO3 (TSE:TOS) last released its earnings results on Tuesday, May 8th. The company reported C($0.06) earnings per share for the quarter, missing the consensus estimate of C($0.04) by C($0.02). The company had revenue of C$0.32 million for the quarter. TSO3 had a negative return on equity of 48.85% and a negative net margin of 34.69%.
Several other analysts also recently commented on TOS. National Bank Financial dropped their price objective on shares of TSO3 from C$1.75 to C$1.50 and set a “sector perform” rating on the stock in a report on Thursday, May 10th. Royal Bank of Canada dropped their price objective on shares of TSO3 from C$1.75 to C$1.50 and set a “sector perform” rating on the stock in a report on Thursday, May 3rd. Finally, Canaccord Genuity dropped their price objective on shares of TSO3 from C$2.40 to C$2.00 in a report on Thursday, May 10th. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of C$1.73.
Shares of TOS stock traded up C$0.03 during trading hours on Thursday, hitting C$1.00. The company’s stock had a trading volume of 36,200 shares, compared to its average volume of 223,950. TSO3 has a 12-month low of C$0.56 and a 12-month high of C$3.30.
In other news, Director Richard Mark Rumble bought 105,900 shares of the firm’s stock in a transaction that occurred on Tuesday, March 27th. The stock was purchased at an average cost of C$0.83 per share, for a total transaction of C$87,897.00.
TSO3 Company Profile
TSO3 Inc engages in the research, development, production, maintenance, sale, and licensing of sterilization processes, related consumable supplies, and accessories for heat and moisture sensitive medical devices. Its principal product is the STERIZONE VP4 sterilizer, a dual sterilant, low temperature sterilization system that utilizes vaporized hydrogen peroxide and ozone that is marketed in Canada and the United States.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TSO3 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TSO3 and related companies with MarketBeat.com's FREE daily email newsletter.